Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
101.49
-0.64 (-0.62%)
Sep 8, 2025, 10:57 AM - Market open
Rhythm Pharmaceuticals Revenue
Rhythm Pharmaceuticals had revenue of $48.50M in the quarter ending June 30, 2025, with 66.80% growth. This brings the company's revenue in the last twelve months to $156.29M, up 53.55% year-over-year. In the year 2024, Rhythm Pharmaceuticals had annual revenue of $130.13M with 68.06% growth.
Revenue (ttm)
$156.29M
Revenue Growth
+53.55%
P/S Ratio
40.77
Revenue / Employee
$552,251
Employees
283
Market Cap
6.74B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 130.13M | 52.70M | 68.06% |
Dec 31, 2023 | 77.43M | 53.79M | 227.56% |
Dec 31, 2022 | 23.64M | 20.48M | 649.46% |
Dec 31, 2021 | 3.15M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
RYTM News
- 11 days ago - Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 18 days ago - Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity - GlobeNewsWire
- 4 weeks ago - Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 6 weeks ago - Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewsWire
- 2 months ago - Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 - GlobeNewsWire
- 2 months ago - Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market - Seeking Alpha
- 2 months ago - Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire